TRIAL DETAIL
Phase I Study of Pazopanib and Vorinostat
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Phase I Study of Pazopanib and Vorinostat |
|||
NCT#: |
||||
Conditions: |
Any type of Cancer |
|||
Status: |
Ongoing, but not recruiting |
|||
Phase: |
1 |
Start Date 04/01/2011 |
Age of Trial (yrs) 13.1 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
KIT/PDGFRA inhibitor + HDAC inhibitor |
|||
Strategy: |
Block KIT + Destroy KIT |
|||
Trial Type: |
GIST not specified. GIST patient enrollment unknown. |
|||
Other Protocol IDs: |
2011-0051 |
|||
Sponsor: |
M.D. Anderson Cancer Center |
|||
Patient Contact: |
Siqing Fu, MD, PHD
713 563-1930 |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
This is a phase I trial to test the safety and maximum tolerated dose of the combination of pazopanib (a KIT/PDGFRA/VEGFR inhibitor also known as Votrient) and vorinostat (a HDAC inhibitor also known as Zolinza or SAHA). |
|||
Trial Links |
Trial Results |
Drug Information |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
1505 Holcombe Blvd. |
Houston |
TX |
77030 |
USA |